Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26663291 | 1.00 | CRBN (0.36) | CRBNOR51E2TACR1DDB1FKBP5 | |
| SCHEMBL26664053 | 1.00 | CRBN (0.36) | CRBNOR51E2TACR1DDB1FKBP5 | |
| SCHEMBL7619497 | 0.88 | OR51E2 (0.38) | CRBNOR51E2FKBP5 | |
| SCHEMBL6921617 | 0.81 | CRBN (0.40) | CRBNOR51E2FKBP5 | |
| SCHEMBL12385740 | 0.78 | ALDH1A1 (0.38) | CRBNOR51E2FKBP5 | |
| SCHEMBL30497332 | 0.77 | MTNR1A (0.31) | — | |
| SCHEMBL1872409 | 0.77 | MTNR1A (0.31) | — | |
| SCHEMBL25703887 | 0.75 | CRBN (0.33) | CRBN | |
| SCHEMBL27382480 | 0.74 | — | — | |
| 2-Pyrrolidone SCHEMBL28180594 | 0.74 | OR51E2 (0.52) | CRBNOR51E2FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260128361-A1 | FUNCTIONAL ALIPHATIC AND/OR AROMATIC AMINE COMPOUNDS OR DERIVATIVES AS ELECTROLYTE ADDITIVES TO REDUCE GAS GENERATION IN LI-ION BATTERIES | ENEVATE CORP (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4695254-A1 | SUBSTITUTED 6-IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12438181-B2 | Functional aliphatic and/or aromatic amine compounds or derivatives as electrolyte additives to reduce gas generation in Li-ion batteries | ENEVATE CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4573096-A1 | INHIBITORS OF MYELOPEROXIDASE | Astrazeneca AB (SE) | 2025-06-25 | — | — | EP | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-2751106-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130338137-A1 | Substituted annellated pyrimidines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-7879848-B2 | good inhibition activity versus Dipeptidyl Peptidase-IV (DPP-IV); Diabetes mellitus, obesity; 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-butyl]-oxazolidin-2-one; compounds having an optionally substituted lactam ring structure | LG LIFE SCIENCES, LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| EP-1863812-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2010-07-14 | — | — | EP | disclosed |
| EP-1863812-A4 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2009-06-24 | — | — | EP | disclosed |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
| EP-1863812-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338137-A1 | Substituted annellated pyrimidines and use thereof | TYMS, TYMP, NUDT1 | CRBN 4534/4885OR51E2 4118/4885TACR1 3664/4885 |
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | CRBN 782/4885OR51E2 4736/4885TACR1 4021/4885 |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | DPP4, DPP7, DPP8 | CRBN 2982/4885OR51E2 2108/4885TACR1 1135/4885 |
| US-20260128361-A1 | FUNCTIONAL ALIPHATIC AND/OR AROMATIC AMINE COMPOUNDS OR DERIVATIVES AS ELECTROLYTE ADDITIVES TO REDUCE GAS GENERATION IN LI-ION BATTERIES | LAGE3, ROS1, CACNA2D3 | CRBN 1810/4885OR51E2 215/4885TACR1 1158/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CRBN 2387/4885OR51E2 1693/4885TACR1 23/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CRBN 2387/4885OR51E2 1693/4885TACR1 23/4885 |
| US-20140179682-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | CRBN 4138/4885OR51E2 1219/4885TACR1 196/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CRBN 2063/4885OR51E2 2908/4885TACR1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.